The Hepatocellular Carcinoma (HCC) Genomic Consortium is a scientific platform created in 2005 devoted to the study of the molecular pathogenesis of liver cancer. It was established in response to a set of principals in biomedical research that primed (1) collaboration, (2) multi-discipline approaches and (3) translation of research from bench to bedside in liver cancer. Prof Josep M Llovet, a renowned researcher in the field, leads the Consortium from Mount Sinai School of Medicine.
The core institutions are:
The Consortium brings together an outstanding range of complementary research, clinical and technological skills and includes experts in different disciplines such as hepatology, surgery, molecular biology, pathology, oncology, radiology, computational biology and biostatistics. They have collaborated in numerous research projects covering several translational areas of liver cancer research including molecular classification, identification of novel oncogenes and tumor suppressors, and validation of novel therapeutic targets in experimental models of the disease. The long-term goal of the Consortium is to unravel the main drivers of liver cancer development, identify novel targets for therapies and ultimately improve the prognosis of this disease. In 2009, it was recognized with the Landon Foundation – American Association for Cancer Research award for International Collaboration.